CGF 166

Drug Profile

CGF 166

Alternative Names: CGF166; Hearing loss gene therapy

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Baylor College of Medicine
  • Developer GenVec; Novartis
  • Class Gene therapies
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hearing loss

Most Recent Events

  • 25 Jul 2016 US FDA lifts clinical hold on phase I/II clinical trial in Hearing loss
  • 23 May 2016 Novartis reinitiates enrolment in a phase I/II trial for Hearing loss in USA (NCT02132130)
  • 09 May 2016 DSMB recommends initiation of a phase I/II trial in Hearing loss in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top